ALX Oncology (ALXO) reported a GAAP net loss of $21.8 million, or $0.15 per basic and diluted share, for the third quarter ended September 30, 2026. Cash, cash equivalents and investments totaled $147.2 million at quarter-end.
The company expects safety and early efficacy data from its Phase 1 ALX2004 study in December 2026 and topline data from approximately 120 patients in the Phase 2 ASPEN-09-Breast trial in the second half of 2027.
- Third-quarter R&D expenses were $17.5 million, compared with $17.4 million a year earlier.
- Third-quarter G&A expenses were $5.5 million, compared with $5.1 million in the prior-year period.
- ALX Oncology said its cash, cash equivalents and investments are sufficient to fund planned operations through the first half of 2028.
- The company plans to host a KOL webinar in December to review ALX2004 results from 35 patients enrolled to date.
$ALXO Insider Trading Activity
$ALXO insiders have traded $ALXO stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ALXO stock by insiders over the last 6 months:
- JASON LETTMANN (CHIEF EXECUTIVE OFFICER) sold 2,230 shares for an estimated $4,303
- SHELLY WONG (SVP, FINANCE AND CAO) has made 0 purchases and 2 sales selling 1,977 shares for an estimated $3,970.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ALXO Hedge Fund Activity
We have seen 54 institutional investors add shares of $ALXO stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC removed 7,356,362 shares (-56.5%) from their portfolio in Q2 2026, for an estimated $15,227,669
- VIVO CAPITAL, LLC removed 3,184,713 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $4,426,751
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,000,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $4,139,999
- SQUADRON CAPITAL MANAGEMENT LLC removed 1,460,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $3,022,199
- FMR LLC added 1,331,335 shares (+10053.9%) to their portfolio in Q3 2026, for an estimated $1,850,555
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 1,205,750 shares (-90.7%) from their portfolio in Q2 2026, for an estimated $2,495,902
- SILVERARC CAPITAL MANAGEMENT, LLC added 821,203 shares (+14.3%) to their portfolio in Q3 2026, for an estimated $1,141,472
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.